Tiny study on vaccine response in heart transplant patients ends early
NCT ID NCT04845945
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aimed to measure how well heart transplant candidates and recipients respond to standard pneumococcal vaccines using two blood tests. Only 4 people enrolled before the study was terminated. Because it was so small, it provides very limited information about vaccine effectiveness in this group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PCV15 and PPSV23 (pneumococcal vaccines)
- What this could lead to
- If successful, this could help doctors understand if standard pneumococcal vaccines work well in heart transplant patients.
- What could go wrong
- The study was terminated early with only 4 participants, so results are very limited and may not apply to others.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART TRANSPLANT INFECTION PREVENTION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Montefiore Medical Center, Infectious Diseases
The Bronx, New York, 10467, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.